Insights from multimodal datasets on the
platform fuel cancer research in Canada
BOSTON and ROLLE, Switzerland, Jan. 8, 2024
/PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native
software company and a leader in data-driven medicine, today
announced a collaboration with Exactis Innovation, based in
Montreal, Quebec, who will
contribute to cancer research and data-driven decision-making
through SOPHiA GENETICS' multimodal real-world data offering.
Exactis Innovation is a non-profit network of hospital partners
across Canada dedicated to
improving cancer survivorship through the acceleration of
data-driven decision-making. Exactis will join the SOPHiA DDM™
network and leverage the SOPHiA DDM™ platform to access global
real-world data insights from multimodal datasets. By joining the
SOPHiA DDM™ network, Exactis researchers will access to a global
network of data that will provide robust, diverse insights to help
support research for its Canadian population.
"Our enhanced focus on real-world data positions us as a key
resource for impartial insights for both industry and public
sectors. Our participation in contributing to, and learning from,
the collective intelligence enabled by SOPHiA GENETICS stems from
our belief that the path to superior data-driven decisions lies in
overcoming borders and utilizing top-tier, ready-to-use real world
data," said Kostas Trakas,
PhD., CEO, Exactis Innovation.
"It is our continued goal to improve health outcomes for
patients globally by equipping local health institutions with the
technology needed to exercise data-driven medicine," said Jurgi
Camblong, PhD., CEO and Co-founder of SOPHiA GENETICS. "As
health data consumption grows and becomes increasingly complex and
multifaceted, it is imperative that healthcare organizations have
the ability to process data in a timely manner and receive highly
accurate results. SOPHiA GENETICS and Exactis Innovation have the
shared vision to improve cancer survivorship in Canada by unlocking insights from medical data
and contributing to a global collective intelligence."
The collaboration will also enable Exactis to implement leading
cancer testing solutions for its patient population, including
MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ and HRD
testing. The SOPHiA DDM™ Platform will support Exactis in its
ability to increase the volume and speed of next-generation
sequencing (NGS) testing and tumor profiling.
"From our modest beginnings in Montreal, our network now includes 16 cancer
sites throughout Canada. Our
collaboration with SOPHiA GENETICS empowers us with advanced tools,
enhancing our capabilities in data-driven medicine. This
partnership places Canadians at the forefront of a global
initiative, leveraging real world data to elevate patient care,
inform critical health decisions, and foster groundbreaking
discoveries," said Gerald
Batist, MD, Chief Medical Officer of Exactis Innovation
and Director of the Segal Cancer Centre at the Jewish General
Hospital.
Exactis leads Canada's most
extensive pan-cancer research initiative, encompassing nearly
10,000 patients.
J.P. Morgan Healthcare Conference
Jurgi Camblong,
PhD., CEO and Co-founder of SOPHiA GENETICS, will present at the
42nd annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 9:00 a.m. PST. More details can be found at
ir.sophiagenetics.com.
For more information on SOPHiA GENETICS, visit
SOPHiAGENETICS.com or connect on X, LinkedIn, Facebook, and
Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on X, LinkedIn, Facebook, and Instagram. Where others
see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management's beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/exactis-innovation-and-sophia-genetics-announce-collaboration-on-multimodal-data-analytics-302028250.html
SOURCE SOPHiA GENETICS